annb0t
Top 20
0540 GMT â Hangzhou Tigermedâs nine-month topline results for donât look upbeat to Nomura analyst Jialin Zhang, who lowers projections for the pharma services company. Topline growth decelerated over the nine months, while margins narrowed, Nomura says. Nomura lowers A share target 9.3% to CNY75.72 but keeps a buy rating.
Continue reading
>>> Read more: Health Care Roundup: Market Talk
Continue reading
>>> Read more: Health Care Roundup: Market Talk